Prophylactic Treatment With Atorvastatin for Episodic Migraine.

The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be confirmed in a larger, multicenter, randomized controlled parallel group study. In addition it will be investigated whether 1) there is an effect of a daily dose of 20mg Atorvastatin, 2) whether the favorable side effect profile, seen in previous studies, can be confirmed, and whether it is even better with the smaller dose, and 3) estimating the cost of Atorvastatin treatment, considering cost of medicine, cost of acute attack medicine, and cost of lost worktime.

NCT Number	NCT06248671
Lead Sponsor	St. Olavs Hospital Collaborators: Haukeland University Hospital, University Hospital of North Norway, University Hospital, Akershus, Ullevaal University Hospital
Conditions	Episodic Migraine
Enrollment	450 participants
Start Date	2024-05-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-07-14